Year-End Report

CLARK & WEINSTOCK for PHRMA

Period Year-End 2007 Filed Feb 6, 2008

Official filing
Firm
CLARK & WEINSTOCK
Client
PHRMA
Income
$120,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Doha/Cancun. Australia Free Trade Negotiations.

LobbyistCovered position, as disclosed
DAVID J BERTEAU CHIEF OF STAFF, REP. TIM WALZ
ED KUTLER N/A
DIRKSEN LEHMAN —
JONATHAN SCHWANTES N/A
DEIRDRE STACH N/A
VIN WEBER N/A

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Executive Office of the President (EOP); U.S. Trade Representative (USTR)

Medicare/Medicaid MMM

Deficit Reduction Act. H.R.3161, Agriculture, Rural Development, Food & Drug Administration and Related Agencies Appropriations Act, 2008, sections related to FDA funding.

LobbyistCovered position, as disclosed
DAVID J BERTEAU CHIEF OF STAFF, REP. TIM WALZ
ED KUTLER N/A
DIRKSEN LEHMAN —
JONATHAN SCHWANTES N/A
DEIRDRE STACH N/A
VIN WEBER N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Bills named: H.R. 3161 (110th)

Government Issues GOV

H.R.3161, Agriculture, Rural Development, Food & Drug Administration and Related Agencies Appropriations Act, 2008, sections related to FDA funding. S.251, Pharmaceutical Market Access and Drug Safety Act of 2007, relating to importation.

LobbyistCovered position, as disclosed
DAVID J BERTEAU CHIEF OF STAFF, REP. TIM WALZ
ED KUTLER N/A
DIRKSEN LEHMAN —
JONATHAN SCHWANTES N/A
DEIRDRE STACH N/A
VIN WEBER N/A

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Bills named: S. 251 (110th), H.R. 3161 (110th)

Medical/Disease Research/Clinical Labs MED

H.R.3161, Agriculture, Rural Development, Food & Drug Administration and Related Agencies Appropriations Act, 2008, sections related to FDA funding. S.51, Preserve Access to Affordable Generics Act; sections relating to substitution of generic drugs for innovator products.

LobbyistCovered position, as disclosed
DAVID J BERTEAU CHIEF OF STAFF, REP. TIM WALZ
ED KUTLER N/A
DIRKSEN LEHMAN —
JONATHAN SCHWANTES N/A
DEIRDRE STACH N/A
VIN WEBER N/A

Contacted: Executive Office of the President (EOP); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: S. 51 (110th), H.R. 3161 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.